Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck/Schering-Plough Initiate Vytorin Acute Coronary Syndrome Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

The two-year, 10,000-patient IMPROVE IT study will evaluate the Zetia/Zocor combination's morbidity/mortality risk reduction compared to Zocor alone. The trial will compare Vytorin 10 mg/40 mg to Zocor 40 mg in patients with acute coronary syndrome.

You may also be interested in...



Vytorin Captures 2% Of New Prescriptions In Cholesterol Market

Merck/Schering’s fixed-dose combination is ahead of AstraZeneca’s Crestor at a similar time during its launch, Schering-Plough says. Schering is also pleased with Vytorin’s level of managed care access.

Spectrum’s Iso-Vorin Could Clear FDA For Osteosarcoma By First Quarter

The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.

Thelin's Third "Approvable" Letter Recommends Additional Clinical Trial

Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel